DexCom Inc
DXCM-
DexCom Inc. gained 0.9% to $84.89 after the provider of monitoring systems for diabetes management reported an 8% revenue growth in the fourth quarter ending in December.
Revenue increased to $1.11 billion from $1.03 billion, net income fell to $151.7 million from $256.3 million, and earnings per diluted share dropped to 38 cents from 62 cents a year ago.
For fiscal 2025, the company estimated revenue of $4.60 billion, up 14% from $4.03 billion a year ago.
Feb 14, 2025 -
DexCom declined 3.5% to $72.33 despite the company reporting higher-than-expected quarterly earnings, but slower revenue growth weighed on the stock.
Oct 25, 2024 -
Dexcom said revenue in the December quarter increased 17% to $815.2 million and net income rose to $91.8 million from $5.3 million and diluted EPS increased to 22 cents from 1 cents a year ago.
Feb 10, 2023
|
|
| |
|
| Trading Volume | 94,762 |
|
|
140.38 - 67.92 |
| Market Cap Full | $ 26.9B |
Quarterly +
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Q1 | - | 4.2% | 11.8% | 2.6% |
| Q2 | - | - | -5.1% | 10.6% |
| Q3 | - | - | 2.3% | -27.4% |
| Q4 | - | - | 11.4% | 31.2% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2025 | |||||||||||
| 4.2 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| -2.2 | -5.2 | 20.6 | -5.8 | - | - | - | 2.3 | - | - | - | 0.1 |
| 2023 | |||||||||||
| -5.4 | 3.7 | 4.7 | 4.4 | -3.4 | 9.6 | -3.1 | -18.9 | -7.6 | -4.8 | 30.1 | 7.4 |
| 2022 | |||||||||||
| -20.3 | -5.1 | 25.7 | -20.4 | -27.1 | -75 | 10.1 | 0.2 | -2 | 50 | -3.7 | -2.6 |
| 2021 | |||||||||||
| 1.4 | 4.4 | -8.1 | 7.3 | -4 | 15.2 | 20.7 | 2.7 | 3.8 | 12.3 | -8.8 | -4 |
EPS
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Q1 | 0.1 | 0.2 | 0.4 |
| Q2 | 0.3 | 0.1 | 0.6 |
| Q3 | 0.3 | 0.2 | 0.7 |
| Q4 | 0 | 0.2 | -0.2 |
| A | 0.69 | 0.8 | 0.5 |